Inogen Appoints Vafa Jamali, Expands Board Expertise

Inogen, Inc., a leader in respiratory medical technology, has announced Vafa Jamali as a new independent director on its Board, effective June 15, 2026. This strategic appointment promises to enhance Inogen’s executive leadership, leveraging Jamali’s extensive experience in medical devices to foster growth and innovation within the company.

The addition of Vafa Jamali to Inogen’s Board comes at a pivotal time, as the company expands its focus from a single product oxygen provider to a diversified respiratory care platform. Jamali’s impressive track record includes leadership roles at ZimVie, Covidien, and Medtronic, where he notably contributed to significant growth and improved financial outcomes. His experience in optimizing portfolios and driving strategic execution is expected to align with Inogen’s goals of boosting revenue and advancing profitability. The cooperation agreement with Kent Lake Partners LP further underlines the shared vision of advancing Inogen’s strategic priorities, underscoring the importance of Jamali’s role in guiding Inogen’s path towards enhanced patient outcomes and broader healthcare system benefits.

The appointment of Vafa Jamali to Inogen’s Board marks a significant step forward for the company as it seeks to accelerate growth within the respiratory care market. With Jamali’s seasoned industry insights, Inogen is well-positioned to capitalize on new opportunities and continue its trajectory of strong financial performance and innovation.